glp-1 kidney disease GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal

Costco's Semaglutide Launch: Is It Really the Best Deal for Weight Loss? GLP1 pills vs. injections: Which works better, and what are the side effects? ASAM eLearning: Semaglutide Circus: Glucagon Like Peptide 1 (GLP 1) Receptor Agonists to Treat Addiction A new study published in Stem Cell Reports from Mayo Clinic uses #stemcells to model diabetic alpha cell dysfunction. SC cells mimic glucagon hypersecretion and sunitinib (tyrosine kinase inhibitor) protects against ER Glucagon Like Peptide 1 Receptor Agonists and Dual Glucose Dependent Insulinotropic Polypeptide Glucagon Like Peptide 1 Receptor Agonists in the Treatment of Obesity Metabolic Syndrome, Prediabetes Diabetes and Non Alcoholic Fatty Liver DiseaseCurrent Sarcopenia in the era of GLP 1 receptor agonists: Implications for the internist The American Journal of Medicine